Endocrine immune-related adverse events in advanced lung cancer patients receiving immune checkpoint inhibitors: incidence, predictors and outcomes
e-irAEs occurred in approximately 10% of advanced lung cancer patients receiving ICIs. Predictors of e-irAE development included female sex, lung metastasis, increased eosinophil count, elevated TSH, and objective response to ICIs. Patients with e-irAE occurrence tended to have a favorable survival outcome.
Authors
- Dan Liu
- Jiarui Zhang (ORCID: https://orcid.org/0000-0003-1593-444X)
- Sha Liu (ORCID: https://orcid.org/0000-0002-8271-3922)
- Yufang Xie
- Huohuo Zhang
- Weimin Li
- Qi Qi (ORCID: https://orcid.org/0009-0005-5107-7168)
- Linhui Yang
- J B Zhu
- Rui Xu
- Xianya Hu
- Wanqin Fang
- Yi Liu
- Jiadi Gan
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-1064
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00